By Kanchan Joshi | 19 Nov, 2021
IPCA Labs: weak exports, API sales, rising costs pose near term challenges
IPCA Laboratories Ltd has maintained robust performance in the domestic market. Given a strong product portfolio of pain management, anti-bacterial drugs, among others, as well as strong institutional business, prospects remain strong. Domestic formulations sales grew 30% year-on-year (YoY) during Q2.While domestic formulations, contributing 45% to overall sales, remained on a strong wicket, tepid...
Live Comments
Queen_Of_Futures1 2023-05-19 15:35:12
now fund raising will be easy for adani. good to go from here. cherss👍
Login & Reply Like(0) Dislike(0) Repost SpamSHIVSHANKAR 2022-08-31 08:44:35
Today it will touch 940.
Login & Reply Like(0) Dislike(0) Repost SpamPalkin 2022-08-23 17:02:51
its a buy from most of the investors and analysts😉 one great news can increase the price of this shares. its a Buy buy buy☺️
Login & Reply Like(0) Dislike(0) Repost SpamSEMU 2022-08-23 16:57:24
its in bull run😉 keep buying for a whopping profits ☺️
Login & Reply Like(0) Dislike(0) Repost SpamBrijesh01 2022-08-17 19:46:00
Its in a bull run. Buy IPCA labs for huge profits. Next targets --- 985, 1010, 1080, 1300
Login & Reply Like(0) Dislike(0) Repost Spamanibillon02 2022-08-17 19:27:58
Its in a bull run. Buy IPCA labs for huge profits. Next targets --- 985, 1010, 1080, 1300
Login & Reply Like(0) Dislike(0) Repost Spamparvin 2022-08-17 09:53:40
There are lot of companies which declared bad June Qrt results but still out performing share price ,while IPCA has become a non performer in last one year
Login & Reply Like(0) Dislike(0) Repost SpamSunil 2022-08-12 13:56:36
buy ipca 900 call cmp 41 target 70 sl 30
Login & Reply Like(0) Dislike(0) Repost SpamPiyu 2022-02-11 12:27:49
IPCA LAB 17.8 🛩️🛩️ THOSE GOT NOW TIME TO RELISH 🧇
Login & Reply Like(0) Dislike(0) Repost Spam